📰 Similis Bio News
Similis Bio News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Similis Bio. Real-time updates on events, politics, business and more.
February 20, 2023
Takeda published the results of Ph III trials of vedolizumab in the prevention of intestinal acute graft-versus-host disease (aGvHD) in patients…
February 14, 2023
JSR Life Sciences, LLC ("JSR") today announced that Similis Bio ("Similis"), its business unit focused on biosimilar development, has announced plans to enter into a partnership with Novel351k to co-develop
November 8, 2022
On October 25, 2022, JSR Life Sciences and Blau Farmaceutica announced that Similis Bio, JSR Life Sciences's business unit focused on biosimilar development, has signed its first development and license agreement...
November 7, 2022
On October 25, 2022, JSR Life Sciences and Blau Farmaceutica announced that Similis Bio, JSR Life Sciences’s business unit focused on biosimilar development, has signed its first...
October 25, 2022
JSR Life Sciences, LLC (JSR) and Blau Farmaceutica (Blau) (public company in Brazil B3 – BLAU3) today announced that Similis Bio (“Similis”), its recently launched business unit focused on biosimilar development, has signed its first development and license agreement with Blau Farmacêutica (“Blau”). The agreement ...
May 26, 2022
JSR Life Sciences recently announced its launch of a new business division, “Similis Bio,” intended to help biosimilar drug developers “improve the efficiency and cost of biosimilar...
May 10, 2022
Newly launched business line leverages the combined experience and technical knowledge of leaders in analytical, cell-line, and process development to reduce up-front time and resource costs for biosimilar